CRVO on Nasdaq

CervoMed Inc.

We are a clinical-stage biotechnology company developing treatments for age-related brain disorders.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with XBiotech Inc., Kala Pharmaceuticals (United States) or CHINA PHARMA HOLDINGS, INC., or pick any stock.

  • TickerCRVO on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersBoston, Massachusetts1
  • Incorporated inDE2
  • Business address20 Park Plaza, Suite 424, Boston, Ma 021162
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company developing treatments for age-related brain disorders. Our lead drug candidate, neflamapimod, is an investigational, orally administered small-molecule drug that readily crosses the blood brain barrier and selectively inhibits the enzyme p38α, a key driver of neuroinflammation and synaptic dysfunction. By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of DLB, our lead indication, as well as nfvPPA, RAS, and ALS.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-706.2%Operating margin4
-673.1%Net margin4
-58.9%Revenue growth, 20254
-148.0%Return on equity4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$21.8M

Out of $4.0M in revenue.4 The company lost money this year.

Financial statements

Revenue564$4.0M in 2025
0$2.5M$5.0M$7.5M$10.0M2022: $0$020222023: $7.1M$7.1M20232024: $9.7M$9.7M2024+36%2025: $4.0M$4.0M2025−59%
Operating income789564-$28.3M in 2025+145% since 2019
-$30.0M-$20.0M-$10.0M02019: -$11.6M-$11.6M20192020: -$16.0M-$16.0M2020+38%2021: -$24.7M-$24.7M2021+54%2022: -$3.5M-$3.5M2022−86%2023: -$7.8M-$7.8M2023+125%2024: -$18.2M-$18.2M2024+133%2025: -$28.3M-$28.3M2025+55%
Net income789564-$27.0M in 2025+129% since 2019
-$30.0M-$20.0M-$10.0M02019: -$11.8M-$11.8M20192020: -$14.2M-$14.2M2020+20%2021: -$24.1M-$24.1M2021+70%2022: -$5.8M-$5.8M2022−76%2023: -$2.2M-$2.2M2023−63%2024: -$16.3M-$16.3M2024+650%2025: -$27.0M-$27.0M2025+66%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Grant revenue$4.0M$9.7M
Research and development$21.8M$18.8M
General and administrative$10.5M$9.2M
Total operating expenses$32.3M$28.0M
Loss from operations-$28.3M-$18.2M
Other expense-$8.3K-$991
Interest income$1.3M$1.9M
Total other income, net$1.3M$1.9M
Net loss-$27.0M-$16.3M
Net loss per share of common stock, basic and diluted (in dollars per share)-$2.98-$2.02
Weighted average shares outstanding, basic and diluted (in shares)9.0M shares8.1M shares
Net unrealized (loss) gain on marketable securities-$50.4K$56.2K
Total comprehensive loss-$27.0M-$16.2M

Compare CervoMed Inc. with another company

Leadership

Who has led CervoMed Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Paul Feller2010
  2. Stephen M. Simes2014
  3. David G. Kalergis2016–2020
  4. John J. Alam2023–now

Chair

  1. Paul Feller2008
  2. Sol J. Barer2013–2014
  3. David G. Kalergis2016–2020

President

  1. Yael Schwartz2013–2014
  2. David Sherris2014
  3. John J. Alam2023–now

Chief financial officer

  1. Philip B. Donenberg2014
  2. William Karl Hornung2018–2022
  3. John William Tanner2023–2024
  4. William Robert Elder2024–now
2010201520202025
Board members and other officers (46)

Former names

  • Diffusion Pharmaceuticals Inc.Jan 15, 2016 to Aug 14, 20232
  • RestorGenex CorpMar 10, 2014 to Jan 14, 20162
  • Stratus Media Group, IncJul 30, 2008 to Mar 7, 20142
  • FERIS INTERNATIONAL, INC.Mar 14, 2008 to Jul 16, 20082
  • TITAN MOTORCYCLE CO OF AMERICA INCNov 16, 1998 to Feb 22, 20082

Timeline

  1. Aug 23, 2023New chief executive John J. Alam becomes CEO12
  2. Jan 13, 2016New chief executive David G. Kalergis becomes CEO13
  3. Mar 12, 2014New chief executive Stephen M. Simes becomes CEO14
  4. Apr 15, 2010New chief executive Paul Feller becomes CEO15

Filings

353 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 115 major events, 110 insider forms, 24 large holders, 84 other. The latest 20:

  1. Oct 14, 20268-K EDGAR
  2. Oct 13, 20268-K EDGAR
  3. Oct 9, 20268-K EDGAR
  4. Sep 28, 20268-K EDGAR
  5. Sep 10, 20268-K EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 14, 2026SCHEDULE 13G/A EDGAR
  8. Aug 14, 2026SCHEDULE 13G EDGAR
  9. Aug 14, 2026SCHEDULE 13G EDGAR
  10. Aug 10, 20268-K EDGAR
  11. Aug 7, 2026S-8 EDGAR
  12. Aug 7, 202610-Q EDGAR
  13. Aug 4, 20268-K EDGAR
  14. Jul 14, 20268-K EDGAR
  15. Jul 10, 2026EFFECT EDGAR
  16. Jul 10, 2026424B3 EDGAR
  17. Jul 9, 20268-K EDGAR
  18. Jul 8, 2026SCHEDULE 13G/A EDGAR
  19. Jul 6, 2026S-3 EDGAR
  20. Jun 26, 2026SCHEDULE 13G EDGAR

The 353 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

18 open-market trades by officers, directors and large owners since October 2021: 17 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 11, 2026BOGER JOSHUA SDirectorBuy955,414$3.14$3.0MForm 4
Nov 18, 2025Winton MatthewChief Commercial and BusinessBuy1,500$7.95$11.9KForm 4
Nov 18, 2025ELDER WILLIAM ROBERTCFO, GC & SecretaryBuy2,500$8.32$20.8KForm 4
Nov 17, 2025Winton MatthewChief Commercial and BusinessBuy3,500$8.43$29.5KForm 4
Nov 17, 2025Gregoire SylvieDirectorBuy21,600$8.46$182.7KForm 4
Nov 17, 2025ELDER WILLIAM ROBERTCFO, GC & SecretaryBuy1,000$8.45$8.4KForm 4
Nov 17, 2025ALAM JOHN JCEO & PresidentBuy21,600$8.46$182.7KForm 4
Nov 14, 2025Gregoire SylvieDirectorBuy3,400$7.56$25.7KForm 4
Nov 14, 2025ALAM JOHN JCEO & PresidentBuy3,400$7.56$25.7KForm 4
Nov 14, 2025Winton MatthewChief Commercial and BusinessBuy10,000$7.57$75.7KForm 4
Nov 13, 2025Gregoire SylvieDirectorBuy4,447$7.51$33.4KForm 4
Nov 13, 2025ALAM JOHN JCEO & PresidentBuy4,447$7.51$33.4KForm 4
Nov 12, 2025Gregoire SylvieDirectorBuy5,553$7.35$40.8KForm 4
Nov 12, 2025ELDER WILLIAM ROBERTCFO, GC & SecretaryBuy3,500$7.44$26.0KForm 4
Nov 12, 2025ALAM JOHN JCEO & PresidentBuy5,553$7.35$40.8KForm 4
May 14, 2025ELDER WILLIAM ROBERTCFO, GC & SecretaryBuy4,233$8.46$35.8KForm 4
Aug 27, 2024ELDER WILLIAM ROBERTCFO, GC & SecretaryBuy1,000$18.16$18.2KForm 4
Feb 26, 2024BOGER JOSHUA SDirectorSale36Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 37. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Woodline Partners LP688,987$2.1M0.0%New
Vanguard Capital Management LLC316,202$980.2K0.0%No change
Sabby Management, LLC248,880$771.5K6.4%New
Geode Capital Management, LLC66,923$207.5K0.0%−7,448
BlackRock, Inc.53,845$166.9K0.0%+2,185
Byrne Asset Management LLC51,250$158.9K0.1%+36,550
Citizens Financial Group Inc/ri37,477$116.2K0.0%No change
Vanguard Fiduciary Trust Co36,151$112.1K0.0%No change
Jane Street Group, LLC32,231$99.9K0.0%+13,985
Thompson Davis & Co., Inc.29,750$92.2K0.1%+19,750
Savvy Advisors, Inc.25,922$80.4K0.0%No change
State Street Corp20,527$63.6K0.0%No change
Cetera Investment Advisers19,622$60.8K0.0%−7,715
Summit Financial, LLC18,140$56.2K0.0%New
Russell Investments Group, Ltd.15,363$47.6K0.0%−727
Northern Trust Corp13,318$41.3K0.0%−16,726
Morgan Stanley12,699$39.4K0.0%−727,193
HighTower Advisors, LLC11,919$36.9K0.0%+654
Fmr LLC10,538$32.7K0.0%−502
NFSG Corp3,000$9.3K0.0%No change
Vanguard Global Advisers, LLC2,597$8.1K0.0%No change
Tower Research Capital LLC (TRC)2,173$6.7K0.0%−5
Federation des caisses Desjardins du Quebec1,700$5.3K0.0%No change
Hoey Investments, Inc1,080$3.3K0.0%No change
UBS Group AG992$3.1K0.0%−4,247

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73